KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

AbCellera Biologics (ABCL) Receivables Refunds (2020 - 2022)

AbCellera Biologics filings provide 3 years of Receivables Refunds readings, the most recent being $64.8 million for Q4 2022.

  • Quarterly Receivables Refunds rose 353.84% to $64.8 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $64.8 million through Dec 2022, up 353.84% year-over-year, with the annual reading at $64.8 million for FY2022, 353.84% up from the prior year.
  • Receivables Refunds hit $64.8 million in Q4 2022 for AbCellera Biologics, up from $14.3 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $64.8 million in Q4 2022 and bottomed at $489000.0 in Q4 2020.
  • Average Receivables Refunds over 3 years is $26.5 million, with a median of $14.3 million recorded in 2021.
  • The largest annual shift saw Receivables Refunds surged 2820.65% in 2021 before it skyrocketed 353.84% in 2022.
  • AbCellera Biologics' Receivables Refunds stood at $489000.0 in 2020, then surged by 2820.65% to $14.3 million in 2021, then skyrocketed by 353.84% to $64.8 million in 2022.
  • Per Business Quant, the three most recent readings for ABCL's Receivables Refunds are $64.8 million (Q4 2022), $14.3 million (Q4 2021), and $489000.0 (Q4 2020).